EPO and myelodysplastic syndrome: Recurrent SF3a1 mutations were only present in non-responders to azacitidine (Aza) and erythropoietin (Epo) in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS patients, although they were not able to predict therapeutic response 39.